Abstract: Compositions containing an anesthetic and an extracellular matrix component or fragment thereof and methods for treating pain by topically administering such compositions are described herein.

Abstract: Compositions containing an anesthetic and an extracellular matrix component or fragment thereof and methods for treating pain by topically administering such compositions are described herein.

Abstract: Compositions containing a protease inhibitor for treating viral infections and methods for treating a patient before, during, or after exposure to an infectious agent by administering such compositions are described herein.

Abstract: Compositions that supplement and support nitric oxide availability to skin and methods of use include a first agent that is a precursor of nitric oxide, a second agent that facilitates production of nitric oxide by the first agent, and a third agent that antagonizes (i) nucleotide activation of skeletal muscle ryanodine receptors or (ii) cellular calcium influx. The first, second and third agents are mixed to form a composition suitable for topical application to skin. The composition may include an adenosine, arginine, carnosine, niacinamide, and a magnesium ion source, wherein application of the composition to a skin region increases cutaneous blood flow in the skin region compared to cutaneous blood flow in a similar skin region not treated with the composition, as measured by doppler ultrasound.

Abstract: Compositions that supplement and support nitric oxide availability to skin and methods of use are provided herein.

Abstract: Compositions comprising an active agent and a decoy molecule and methods for treating pain by topically administering such compositions are described herein. The compositions may be powdered. Compositions include a decoy molecule with a specified average molecular weight and no high molecular weight decoy molecule. The extracellular components include hyaluronic acid, collagen, fibronectin, elastin, lectin, and fragments thereof and combinations thereof.

Abstract: Compositions containing a protease inhibitor for treating viral infections and methods for treating a patient before, during, or after exposure to an infectious agent by administering such compositions are described herein.

Abstract: Compositions containing a protease inhibitor for treating viral infections and methods for treating a patient before, during, or after exposure to an infectious agent by administering such compositions are described herein.

Abstract: Compositions containing an anesthetic and an extracellular matrix component or fragment thereof and methods for treating pain by topically administering such compositions are described herein.

Abstract: Compositions comprising an active agent and a decoy molecule and methods for treating pain by topically administering such compositions are described herein. The compositions may be powdered. Compositions include a decoy molecule with a specified average molecular weight and no high molecular weight decoy molecule. The extracellular components include hyaluronic acid, collagen, fibronectin, elastin, lectin, and fragments thereof and combinations thereof.

Abstract: Compositions containing a protease inhibitor for treating viral infections and methods for treating a patient before, during, or after exposure to an infectious agent by administering such compositions are described herein.

Abstract: This invention related to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances.

Abstract: A calcaneal implant for extending the length of a leg of a patient and surgical methods for implanting the implant are described herein.

Abstract: Compositions for transdermal delivery of an active agent and methods for using such compositions are described herein.

Abstract: This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances.

Abstract: Compositions and methods are provided that are useful for the delivery of therapeutic agents, including nucleic acids. The compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Abstract: Compositions and methods are provided that are useful for the delivery of therapeutic agents, including nucleic acids. The compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Abstract: The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligoarginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the invention can add other complementary or beneficial properties for the skin beyond those that are arginine-related.

Abstract: This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin. The compositions may further contain molecules that are not native to botulinum toxin and that bind non-covalently to the botulinum toxin complexes, thereby acting as skin-tropic “adhesion molecules” to improve the ability of the toxin complexes to adhere to and to penetrate the skin epithelium. The compositions have an improved safety profile compared to existing botulinum-containing compositions that are injected subcutaneously. Methods for the use of such compositions are also contemplated by this invention.

Abstract: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.